[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-functional-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-functional-constipation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613072","real-world-study-on-fecal-microbiota-transplantation-long-term-effectiveness-and-safety-statistics-100613072",false,"NCT07261826","Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","Inclusion Criteria:\n\n* Diagnosed with one of the target diseases.\n* Age ≥ 3 years.\n* Have received at least one Fecal Microbiota Transplantation (FMT) treatment.\n* Availability of complete baseline and follow-up data for analysis.\n* Provide signed informed consent (for the prospective cohort) OR consent for the use of clinical data (for the retrospective cohort).\n\nExclusion Criteria:\n\n* Clinical data is severely missing, making efficacy assessment impossible.\n* Presence of severe complications that may jeopardize safety or confound the study results.","ALL","3 Years",{"count":18,"type":19},4000,"ESTIMATED","5 Years","OBSERVATIONAL","This is a large-scale observational study aiming to evaluate the long-term effectiveness and safety of Fecal Microbiota Transplantation (FMT). FMT is a procedure that transfers gut bacteria from healthy donors to patients to restore a balanced gut microbiome.\n\nThe study will follow approximately 4,000 patients who have received or will receive FMT for conditions like recurrent C. difficile infection, inflammatory bowel disease, functional gastrointestinal disorders, and certain neurological conditions.\n\nThe main goals are to:\n\n* Assess the disease remission rates at 3 months, 1 year, and 5 years after FMT.\n* Monitor the long-term safety and any potential side effects.\n* Identify factors that may influence how well a patient responds to the treatment.\n\nThis research will use both existing patient data (retrospective cohort) and newly collected data from future patients (prospective cohort). The findings are expected to help improve and standardize FMT treatment for better patient care.",[24,25,26,27,28,29,30,31,32],"Clostridium Difficile Infection Recurrence","Ulcerative Colitis (UC)","Crohn Disease (CD)","Irritable Bowel Syndrome (IBS)","Chronic Functional Constipation","Chemotherapy-Induced Colitis","PD-1 Associated Enteritis","Autism Spectrum Disorder","Incomplete Intestinal Obstruction","RECRUITING","2025-11-22",{"date":36,"type":37},"2025-12-03","ACTUAL",{"date":39,"type":37},"2025-09-01",{"date":41,"type":19},"2028-06-30",{"name":43,"class":44},"Chen QiYi","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100556566","comparative-study-of-different-dosages-of-vibrabot-capsule-in-the-treatment-of-chronic-functional-constipation-100556566","NCT06526767","Comparative Study of Different Dosages of Vibrabot Capsule in the Treatment of Chronic Functional Constipation","Comparative Study of Different Dosages of Disposable Gastrointestinal Vibrating Capsule (Vibrabot Capsule) in the Treatment of Mild to Moderate Chronic Functional Constipation","Inclusion Criteria:\n\n\\- 1.18 to 85-year-old men and women. 2. People with moderate to severe functional constipation according to Rome IV criteria.\n\nThe Rome IV criteria for functional constipation are as follows:\n\n1. Must include two or more of the following:\n\n   * Straining during more than one-fourth (25%) of defecations;\n   * Lumpy or hard stools (BSFS 1-2) more than one-fourth (25%) of defecations;\n   * Sensation of incomplete evacuation more than one-fourth (25%) of defecations;\n   * Sensation of anorectal obstruction\u002Fblockage more than one-fourth (25%) of defecations;\n   * Manual maneuvers to facilitate more than one fourth (25%) of defecations (e.g., digital evacuation, support of the pelvic floor);\n   * Fewer than 3 spontaneous bowel movements per week;\n2. Loose stools are rarely present without the use of laxatives.\n3. Insufficient criteria for irritable bowel syndrome Criteria fulfilled for the last three months with symptom onset at least six months prior to diagnosis.\n\nSeverity of constipation:\n\n1. Mild: The symptoms are mild and do not affect daily life. Normal BMs can be restored through overall adjustment and medication use in a short time.\n2. Moderate: The symptoms are between mild and severe symptoms.\n3. Severe: The symptoms are severe and persistent, seriously affecting work and life, and requiring medications, and medications cannot be stopped, or medications are ineffective.\n\n   3\\. People who had a colonoscopy within three years before screening and had negative results, or whose colonoscopy results are judged by the investigator as mild anomalies, but the cause of their constipation cannot be explained. If the colonoscopy report is unavailable, the study physician will determine if a colonoscopy is needed. If the subjects undergo a colonoscopy after signing the ICF, they will not enter the treatment period until their BMs return to the baseline level (which takes about 1-4 weeks).\n\n   4\\. People had colonic polyps and a polypectomy (except for endoscopic submucosal dissection (ESD)). Those with a polyp ≤1 cm can be enrolled one month after the polypectomy. Those with a polyp \\>1 cm can be enrolled three months after the polypectomy.\n\n   5\\. People who consent to participate in this trial, can communicate with the investigator, understand and comply with the relevant procedures and requirements during the study (including completing study questionnaires on time, being treated and visited as scheduled, and undergoing relevant examinations), and voluntarily sign the ICF.\n\n   Exclusion Criteria:\n   1. People who are not eligible for surgery or refuse to undergo any abdominal surgery.\n   2. People with known or suspected gastrointestinal obstruction, stenosis, diverticulum, bleeding, malformation, and fistula.\n   3. People allergic to polymeric materials.\n   4. People implanted with cardiac pacemakers and using gastrointestinal pacemakers.\n   5. People with abdominal aortic aneurysms, gastrointestinal vascular lesions, ulcers, and lesions with bleeding tendencies.\n   6. People with dysphagia.\n   7. People with severe depression and anxiety and severe acute gastrointestinal lesions.\n   8. People who had gastrointestinal surgery or a history of surgery that changed the structure of the gastrointestinal tract (except for appendectomy) or people who underwent gastrointestinal ESD in the past three months.\n   9. People with severe hemorrhoids (patients with grade III-IV hemorrhoids according to the Clinical Practice Guidelines for the Management of Hemorrhoids of the American Society of Colon and Rectal Surgeons).\n   10. People who plan to undergo MRI in the near future.\n   11. Pregnant women or women with pregnancy plans in the next year.\n   12. People with other conditions, so the investigator considers them not eligible for this study.","18 Years","85 Years",{"count":56,"type":19},120,"INTERVENTIONAL",[59],"NA","This is a single-center trial that enrolls 120 18- to 85-year-old patients with mild to moderate chronic functional constipation to study the dose-response relationship of the Vibrabot capsule as well as the mechanism of action of the Vibrabot capsule.",[28],[28,63,64,65],"Vibrating Capsule","Dose-response Relationship","Mechanism","2024-07-24",{"date":68,"type":37},"2024-07-30",{"date":70,"type":37},"2024-05-23",{"date":72,"type":19},"2025-12-31",{"name":74,"class":44},"Beijing Tsinghua Chang Gung Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100547508","effect-of-vibration-capsule-on-different-subtypes-of-functional-constipation-100547508","NCT06408883","Effect of Vibration Capsule on Different Subtypes of Functional Constipation","A Prospective Cohort Study On the Efficacy of Vibrating Capsule For Different Subtypes of Chronic Functional Constipation","Inclusion Criteria:\n\nPatients who can be diagnosed with functional constipation according to the Rome IV criteria.\n\nPatients who consent to participate in this trial and voluntarily sign the informed consent form (ICF).\n\nExclusion Criteria:\n\nPeople who are not eligible for surgery or refuse to undergo any abdominal surgery; People with known or suspected gastrointestinal obstruction, stenosis, diverticulum, bleeding, malformation, and fistula.\n\nPeople allergic to polymeric materials; People implanted with cardiac pacemakers and using gastrointestinal pacemakers; People with abdominal aortic aneurysms, gastrointestinal vascular lesions, ulcers, and lesions with bleeding tendencies.\n\nPeople with dysphagia; Pregnant women; People with severe depression and anxiety and severe acute gastrointestinal lesions.\n\nPeople with other conditions, so the investigator considers them not eligible for this study.",{"count":83,"type":19},600,"4 Weeks","This study is a multi-center prospective cohort study, which plans to include 600 patients with chronic functional constipation to treat with Vibrabot capsules and patients will be grouped according to subtypes.\n\nDuring the study, the patients' basic information, baseline constipation status and treatment information, capsule intake during treatment, and concomitant medication will be collected. During the treatment phase, patients follow the doctor's advice to receive Vibrabot capsule treatment and maintain stable dietary intake and exercise according to the constipation diagnosis and treatment guidelines.\n\nDuring the study, patients need to fill in the relevant information during the treatment in the electronic questionnaire in a timely and truthful manner. The treatment effect of the patients is evaluated by assessing the number of occurrences of spontaneous bowel movements (SBM) and complete spontaneous bowel movements (CSBM).",[87,28],"Clinical Study",[63,89,28],"cohort study","NOT_YET_RECRUITING","2024-05-07",{"date":93,"type":37},"2024-05-10",{"date":95,"type":19},"2024-06-01",{"date":97,"type":19},"2026-07-01",{"name":99,"class":44},"Changhai Hospital"]